黑色素瘤BRAF抑制剂耐药机制的研究进展

doi:10.12092/j.issn.1009-2501.2020.05.015

摘要/Abstract

摘要： 黑色素瘤是一种源于黑色素细胞的恶性肿瘤,临床上约50%的黑色素瘤患者发生了BRAF突变。BRAF抑制剂能够作用于突变的BRAF位点,从而迅速对肿瘤细胞发挥增殖抑制和促进凋亡作用,但此后迅速发生的耐药事件严重制约了该类药物的连续使用,所以对于BRAF抑制剂耐药机制的探究非常重要。本文介绍了近年来有关黑色素瘤BRAF抑制剂耐药的相关研究进展,以期为后续的相关研究和临床应用提供一定的参考。

关键词: 黑色素瘤, BRAF抑制剂, 耐药机制, 治疗策略

Abstract: Melanoma is a malignant tumor of melanocyte origin, and BRAF mutations occur in about 50% of melanoma patients clinically. BRAF inhibitors can target mutated BRAF sites, thus rapidly inhibiting the proliferation and promoting apoptosis of tumor cells. However, the subsequent rapid occurrence of drug resistance events seriously restricted the continuous use of such drugs, so it is of great importance to explore the mechanism of BRAF inhibitors resistance. This paper introduces the research progress of BRAF inhibitor resistance in melanoma in recent years, in order to provide some references for the follow-up research and clinical application.

Key words: melanoma, BRAF inhibitors, resistance mechanism, treatment strategies

中图分类号:

王程, 马鹏程, 孙建方, 李弘扬. 黑色素瘤BRAF抑制剂耐药机制的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(5): 576-583.

WANG Cheng, MA Pengcheng, SUN Jianfang, LI Hongyang. Research progress in the mechanism of BRAF inhibitor resistance in melanoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 576-583.

参考文献

[1]Olbryt M. Molecular background of skin melanoma development and progression: therapeutic implications [J]. Postepy Dermatol Alergol, 2019, 36(2): 129-138.
[2]Croce L, Coperchini F, Magri F, et al. The multifaceted anti-cancer effects of BRAF-inhibitors [J]. Oncotarget, 2019, 10(61): 6623-6640.
[3]Romano E, Pradervand S, Paillusson A, et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression [J]. Clin Cancer Res, 2013, 19(20): 5749-5757.
[4]Ahn JH, Hwang SH, Cho HS, et al. Differential gene expression common to acquired and intrinsic resistance to BRAF inhibitor revealed by RNA-Seq analysis [J]. Biomol Ther (Seoul), 2019, 27(3): 302-310.
[5]Kakadia S, Yarlagadda N, Awad R, et al. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma [J]. Onco Targets Ther, 2018, 11: 7095-7107.
[6]Johnson DB, Childress MA, Chalmers ZR, et al. BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy [J]. Pigment Cell Melanoma Res, 2018, 31(3): 432-436.
[7]Luebker SA, Koepsell SA. Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies [J]. Front Oncol, 2019, 9: 268.
[8]Duggan MC, Stiff AR, Bainazar M, et al. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma [J]. Proc Natl Acad Sci U S A, 2017, 114(36): 9629-9634.
[9]Irvine M, Stewart A, Pedersen B, et al. Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma [J]. Oncogenesis, 2018, 7(9): 72.
[10]Misek SA, Appleton KM, Dexheimer TS, et al. Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells [J]. Oncogene, 2020, 39(7): 1466-1483.
[11]Fisher ML, Grun D, Adhikary G, et al. Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells [J]. Oncotarget, 2017, 8(66): 110257-110272.
[12]Feddersen CR, Schillo JL, Varzavand A, et al. Src-dependent DBL family members drive resistance to vemurafenib in human melanoma [J]. Cancer Res, 2019, 79(19): 5074-5087.
[13]Webster MR, Fane ME, Alicea GM, et al. Paradoxical role for wild-type p53 in driving therapy resistance in melanoma [J]. Mol Cell, 2019.
[14]Caporali S, Alvino E, Lacal PM, et al. Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib [J]. Oncotarget, 2017, 8(69): 113472-113493.
[15]Shen S, Faouzi S, Bastide A, et al. An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells [J]. Nat Commun, 2019, 10(1): 5713.
[16]Gupta R, Bugide S, Wang B, et al. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway [J]. Proc Natl Acad Sci U S A, 2019, 116(10): 4583-4591.
[17]Liu X, Zhang SM, McGeary MK, et al. KDM5B promotes drug resistance by regulating melanoma-propagating cell subpopulations [J]. Mol Cancer Ther, 2019, 18(3): 706-717.
[18]Saei A, Eichhorn PJA. Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma [J]. Mol Cell Oncol, 2018, 5(5): e1497862.
[19]Diaz-Martinez M, Benito-Jardon L, Alonso L, et al. miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma [J]. Cancer Res, 2018, 78(4): 1017-1030.
[20]Koetz-Ploch L, Hanniford D, Dolgalev I, et al. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway [J]. Pigment Cell Melanoma Res, 2017, 30(3): 328-338.
[21]Kim JH, Ahn JH, Lee M. Upregulation of microRNA-1246 is associated with BRAF inhibitor resistance in melanoma cells with mutant BRAF [J]. Cancer Res Treat, 2017, 49(4): 947-959.
[22]Pieper N, Zaremba A, Leonardelli S, et al. Evolution of melanoma cross-resistance to CD8(+) T cells and MAPK inhibition in the course of BRAFi treatment [J]. Oncoimmunology, 2018, 7(8): e1450127.
[23]Jiang X, Zhou J, Giobbie-Hurder A, et al. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition [J]. Clin Cancer Res, 2013, 19(3): 598-609.
[24]Kim MH, Kim CG, Kim SK, et al. YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma [J]. Cancer Immunol Res, 2018, 6(3): 255-266.
[25]Hirata E, Girotti MR, Viros A, et al. Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling [J]. Cancer Cell, 2015, 27(4): 574-588.
[26]Ruzzolini J, Peppicelli S, Andreucci E, et al. Everolimus selectively targets vemurafenib resistant BRAF(V600E) melanoma cells adapted to low pH [J]. Cancer Lett, 2017, 408: 43-54.
[27]Basu R, Kulkarni P, Qian Y, et al. Growth hormone upregulates melanocyte-inducing transcription factor expression and activity via JAK2-STAT5 and SRC signaling in GH receptor-positive human melanoma [J]. Cancers (Basel), 2019, 11(9): 1352.
[28]Xiao J, Egger ME, McMasters KM, et al. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines [J]. BMC Cancer, 2018, 18(1): 675.
[29]Cesi G, Philippidou D, Kozar I, et al. A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells [J]. Mol Cancer, 2018, 17(1): 145.
[30]Martin S, Dudek-Peric AM, Garg AD, et al. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF(V600E) inhibitor-resistant metastatic melanoma cells [J]. Autophagy, 2017, 13(9): 1512-1527.
[31]Consoli F, Bersanelli M, Perego G, et al. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma [J]. Clin Transl Oncol, 2020, 22(6): 900-907.
[32]Sun J, Carr MJ, Khushalani NI. Principles of targeted therapy for melanoma [J]. Surg Clin North Am, 2020, 100(1): 175-188.
[33]Garzon-Orjuela N, Prieto-Pinto L, Lasalvia P, et al. Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: A systematic review and network meta-analysis [J]. Dermatol Ther, 2019: e13145.
[34]Trojaniello C, Festino L, Vanella V, et al. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations [J]. Expert Rev Clin Pharmacol, 2019, 12(3): 259-266.
[35]Kattan J, Kattan C, Farhat F, et al. Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report [J]. Anticancer Drugs, 2019, 30(10): 1052-1054.
[36]Valpione S, Carlino MS, Mangana J, et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study [J]. Eur J Cancer, 2018, 91: 116-124.
[37]Tietze JK, Forschner A, Loquai C, et al. The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study [J]. Oncotarget, 2018, 9(76): 34336-34346.
[38]Pelster MS, Amaria RN. Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials [J]. Ther Adv Med Oncol, 2019, 11: 1758835919830826.
[39]Brummer C, Faerber S, Bruss C, et al. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma [J]. Cancer Lett, 2019, 442: 453-463.
[40]Vashisht Gopal YN, Gammon S, Prasad R, et al. A novel mitochondrial inhibitor blocks MAPK pathway and overcomes MAPK inhibitor resistance in melanoma [J]. Clin Cancer Res, 2019, 25(21): 6429-6442.
[41]Hall A, Maynard S, Wu LP, et al. Perturbation of mitochondrial bioenergetics by polycations counteracts resistance to BRAF(E600) inhibition in melanoma cells [J]. J Control Release, 2019, 309: 158-172.
[42]Carpenter EL, Chagani S, Nelson D, et al. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF(V600E) mutation bearing metastatic melanoma cells [J]. Mol Carcinog, 2019, 58(9): 1680-1690.